ANTAGONIST OF TH-1 IMMUNERESPONSE INDUCING CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES

摘要

Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.